Tazemetostat Withdrawl and RECITE
from OncoPharm Hosted by John Bossaer
Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 14 minutes long.
When was this OncoPharm episode published?
This episode was published on March 19, 2026.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.